High-dose folate and dietary purines promote scavenging of peroxynitrite-derived radicals - Clinical potential in inflammatory disorders

Medical Hypotheses

Volumn 73, Issue 5, 2009, Pages 824-834

  McCarty, Mark F ^a   Barroso Aranda, Jorge ^a   Contreras, Francisco ^a  

^a Oasis of Hope Hospital   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; ANTIOXIDANT; CARBONIC ACID; CAROTENOID; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FOLIC ACID; FOLINIC ACID; GAMMA TOCOPHEROL; INOSINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NITROGEN DIOXIDE; NUCLEIC ACID; PEROXYNITRITE; PHYCOCYANOBILIN; PURINE DERIVATIVE; RIBOSE; THIOCTIC ACID; UNCLASSIFIED DRUG; URIC ACID;

ACUTE PANCREATITIS; ALZHEIMER DISEASE; ANGINA PECTORIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CELL DEATH; CELL VIABILITY; CENTRAL NERVOUS SYSTEM DISEASE; COLITIS; CONGESTIVE HEART FAILURE; CYTOTOXICITY; DECOMPOSITION; DEGENERATIVE DISEASE; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIET SUPPLEMENTATION; DIET THERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ENZYME ACTIVATION; ENZYME REGULATION; FLUID THERAPY; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART RIGHT VENTRICLE HYPERTROPHY; HEMORRHAGIC SHOCK; HUMAN; INFLAMMATORY DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; INTERMITTENT CLAUDICATION; ISCHEMIA; KIDNEY DISEASE; MIGRAINE; MULTIPLE SCLEROSIS; MUTAGENESIS; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; SEPTIC SHOCK; SINGLE DRUG DOSE; VASCULAR DISEASE;

DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLIC ACID; FREE RADICAL SCAVENGERS; HUMANS; INFLAMMATION; PEROXYNITROUS ACID; PURINES;

RODENTIA;

EID: 69249223679     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2008.09.058     Document Type: Article

References (268)

1. Shimizu S., Ishii M., Momose K., and Yamamoto T. Role of tetrahydrobiopterin in the function of nitric oxide synthase, and its cytoprotective effect (Review). Int J Mol Med 2 5 (1998) 533-540
2. Milstien S., and Katusic Z. Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. Biochem Biophys Res Commun 263 3 (1999) 681-684
3. Kohnen S.L., Mouithys-Mickalad A.A., by-Dupont G.P., Deby C.M., Lamy M.L., and Noels A.F. Oxidation of tetrahydrobiopterin by peroxynitrite or oxoferryl species occurs by a radical pathway. Free Radic Res 35 6 (2001) 709-721
4. Kuzkaya N., Weissmann N., Harrison D.G., and Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J Biol Chem 278 25 (2003) 22546-22554
5. Xu J., Wu Y., Song P., Zhang M., Wang S., and Zou M.H. Proteasome-dependent degradation of guanosine 5′-triphosphate cyclohydrolase I causes tetrahydrobiopterin deficiency in diabetes mellitus. Circulation 116 8 (2007) 944-953
6. Verhaar M.C., Wever R.M., Kastelein J.J., van D.T., Koomans H.A., and Rabelink T.J. 5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation 97 3 (1998) 237-241
7. Stroes E.S., van Faassen E.E., Yo M., Martasek P., Boer P., Govers R., et al. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res 86 11 (2000) 1129-1134
8. Doshi S.N., McDowell I.F., Moat S.J., Lang D., Newcombe R.G., Kredan M.B., et al. Folate improves endothelial function in coronary artery disease: an effect mediated by reduction of intracellular superoxide?. Arterioscler Thromb Vasc Biol 21 7 (2001) 1196-1202
9. Hyndman M.E., Verma S., Rosenfeld R.J., Anderson T.J., and Parsons H.G. Interaction of 5-methyltetrahydrofolate and tetrahydrobiopterin on endothelial function. Am J Physiol Heart Circ Physiol 282 6 (2002) H2167-H2172
10. Griffith T.M., Chaytor A.T., Bakker L.M., and Edwards D.H. 5-Methyltetrahydrofolate and tetrahydrobiopterin can modulate electrotonically mediated endothelium-dependent vascular relaxation. Proc Natl Acad Sci USA 102 19 (2005) 7008-7013
11. Moat S.J., Clarke Z.L., Madhavan A.K., Lewis M.J., and Lang D. Folic acid reverses endothelial dysfunction induced by inhibition of tetrahydrobiopterin biosynthesis. Eur J Pharmacol 530 3 (2006) 250-258
12. Antoniades C., Shirodaria C., Warrick N., Cai S., de B.J., Lee J., et al. 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 114 11 (2006) 1193-1201
13. Rezk BM, Haenen GR, van der Vijgh WJ, Bast A. Tetrahydrofolate and 5-methyltetrahydrofolate are folates with high antioxidant activity. Identification of the antioxidant pharmacophore. FEBS Lett 2003;555(3):601-5.
14. Squadrito G.L., Cueto R., Splenser A.E., Valavanidis A., Zhang H., Uppu R.M., et al. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys 376 2 (2000) 333-337
15. Alvarez B., and Radi R. Peroxynitrite reactivity with amino acids and proteins. Amino Acids 25 3-4 (2003) 295-311
16. Zou M.H., and Ullrich V. Peroxynitrite formed by simultaneous generation of nitric oxide and superoxide selectively inhibits bovine aortic prostacyclin synthase. FEBS Lett 382 1-2 (1996) 101-104
17. Zou M., Martin C., and Ullrich V. Tyrosine nitration as a mechanism of selective inactivation of prostacyclin synthase by peroxynitrite. Biol Chem 378 7 (1997) 707-713
18. Schmidt P., Youhnovski N., Daiber A., Balan A., Arsic M., Bachschmid M., et al. Specific nitration at tyrosine 430 revealed by high resolution mass spectrometry as basis for redox regulation of bovine prostacyclin synthase. J Biol Chem 278 15 (2003) 12813-12819
19. Venugopal S.K., Devaraj S., and Jialal I. C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation 108 14 (2003) 1676-1678
20. Frassetto L., Morris Jr. R.C., and Sebastian A. Long-term persistence of the urine calcium-lowering effect of potassium bicarbonate in postmenopausal women. J Clin Endocrinol Metab 90 2 (2005) 831-834
21. Shukla N., Angelini G.D., and Jeremy J.Y. The administration of folic acid reduces intravascular oxidative stress in diabetic rabbits. Metabolism 57 6 (2008) 774-781
22. Zou M., Jendral M., and Ullrich V. Prostaglandin endoperoxide-dependent vasospasm in bovine coronary arteries after nitration of prostacyclin synthase. Br J Pharmacol 126 6 (1999) 1283-1292
23. Zou M.H., and Bachschmid M. Hypoxia-reoxygenation triggers coronary vasospasm in isolated bovine coronary arteries via tyrosine nitration of prostacyclin synthase. J Exp Med 190 1 (1999) 135-139
24. Zou M.H. Peroxynitrite and protein tyrosine nitration of prostacyclin synthase. Prostagland Other Lipid Mediat 82 1-4 (2007) 119-127
25. Joshi G.P., Gertler R., and Fricker R. Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs. Anesth Analg 105 6 (2007) 1793-1804
26. Caughey G.E., Cleland L.G., Penglis P.S., Gamble J.R., and James M.J. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. J Immunol 167 5 (2001) 2831-2838
27. Spinella M.J., Brigle K.E., Sierra E.E., and Goldman I.D. Distinguishing between folate receptor-alpha-mediated transport and reduced folate carrier-mediated transport in L1210 leukemia cells. J Biol Chem 270 14 (1995) 7842-7849
28. Huang A., Vita J.A., Venema R.C., and Keaney Jr. J.F. Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular tetrahydrobiopterin. J Biol Chem 275 23 (2000) 17399-17406
29. Offer T., Ames B.N., Bailey S.W., Sabens E.A., Nozawa M., and Ayling J.E. 5-Methyltetrahydrofolate inhibits photosensitization reactions and strand breaks in DNA. FASEB J 21 9 (2007) 2101-2107
30. McCarty M.F. Oster rediscovered - mega-dose folate for symptomatic atherosclerosis. Med Hypotheses 69 2 (2007) 325-332
31. Moens A.L., Claeys M.J., Wuyts F.L., Goovaerts I., Van H.E., Wendelen L.C., et al. Effect of folic acid on endothelial function following acute myocardial infarction. Am J Cardiol 99 4 (2007) 476-481
32. Moens A.L., Champion H.C., Claeys M.J., Tavazzi B., Kaminski P.M., Wolin M.S., et al. High-dose folic acid pretreatment blunts cardiac dysfunction during ischemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury. Circulation 117 (2008) 1810-1819
33. Szabo G., and Bahrle S. Role of nitrosative stress and poly(ADP-ribose) polymerase activation in myocardial reperfusion injury. Curr Vasc Pharmacol 3 3 (2005) 215-220
34. Levrand S., Vannay-Bouchiche C., Pesse B., Pacher P., Feihl F., Waeber B., et al. Peroxynitrite is a major trigger of cardiomyocyte apoptosis in vitro and in vivo. Free Radic Biol Med 41 6 (2006) 886-895
35. Lamberts R.R., Caldenhoven E., Lansink M., Witte G., Vaessen R.J., St Cyr J.A., et al. Preservation of diastolic function in monocrotaline-induced right ventricular hypertrophy in rats. Am J Physiol Heart Circ Physiol 293 3 (2007) H1869-H1876
36. Pliml W., von A.T., Stablein A., Hofmann H., Zimmer H.G., and Erdmann E. Effects of ribose on exercise-induced ischaemia in stable coronary artery disease. Lancet 340 8818 (1992) 507-510
37. Omran H., Illien S., MacCarter D., St C.J., and Luderitz B. D-Ribose improves diastolic function and quality of life in congestive heart failure patients: a prospective feasibility study. Eur J Heart Fail 5 5 (2003) 615-619
38. Pacher P., Schulz R., Liaudet L., and Szabo C. Nitrosative stress and pharmacological modulation of heart failure. Trends Pharmacol Sci 26 6 (2005) 302-310
39. Weitman S.D., Weinberg A.G., Coney L.R., Zurawski V.R., Jennings D.S., and Kamen B.A. Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. Cancer Res 52 23 (1992) 6708-6711
40. Wu D., and Pardridge W.M. Blood-brain barrier transport of reduced folic acid. Pharm Res 16 3 (1999) 415-419
41. Ramaekers V.T., Rothenberg S.P., Sequeira J.M., Opladen T., Blau N., Quadros E.V., et al. Autoantibodies to folate receptors in the cerebral folate deficiency syndrome. New Engl J Med 352 19 (2005) 1985-1991
42. Malinski T. Nitric oxide and nitroxidative stress in Alzheimer's disease. J Alzheimers Dis 11 2 (2007 May) 207-218
43. Horiguchi T., Uryu K., Giasson B.I., Ischiropoulos H., Lightfoot R., Bellmann C., et al. Nitration of tau protein is linked to neurodegeneration in tauopathies. Am J Pathol 163 3 (2003) 1021-1031
44. Ebadi M., and Sharma S.K. Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease. Antioxid Redox Signal 5 3 (2003) 319-335
45. Urushitani M., and Shimohama S. The role of nitric oxide in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2 2 (2001) 71-81
46. Torreilles F., Salman-Tabcheh S., Guerin M., and Torreilles J. Neurodegenerative disorders: the role of peroxynitrite. Brain Res Brain Res Rev 30 2 (1999) 153-163
47. McCarty M.F. Down-regulation of microglial activation may represent a practical strategy for combating neurodegenerative disorders. Med Hypotheses 67 2 (2006) 251-269
48. Pacher P., Beckman J.S., and Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87 1 (2007) 315-424
49. Sawa T., and Ohshima H. Nitrative DNA damage in inflammation and its possible role in carcinogenesis. Nitric Oxide 14 2 (2006) 91-100
50. Sawa T., Tatemichi M., Akaike T., Barbin A., and Ohshima H. Analysis of urinary 8-nitroguanine, a marker of nitrative nucleic acid damage, by high-performance liquid chromatography-electrochemical detection coupled with immunoaffinity purification: association with cigarette smoking. Free Radic Biol Med 40 4 (2006) 711-720
51. Yoshie Y., and Ohshima H. Synergistic induction of DNA strand breakage by cigarette tar and nitric oxide. Carcinogenesis 18 7 (1997) 1359-1363
52. Thuraisingham R.C., Nott C.A., Dodd S.M., and Yaqoob M.M. Increased nitrotyrosine staining in kidneys from patients with diabetic nephropathy. Kidney Int 57 5 (2000) 1968-1972
53. Ceriello A., Mercuri F., Quagliaro L., Assaloni R., Motz E., Tonutti L., et al. Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia 44 7 (2001) 834-838
54. Du X., Matsumura T., Edelstein D., Rossetti L., Zsengeller Z., Szabo C., et al. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 112 7 (2003) 1049-1057
55. Cowell R.M., and Russell J.W. Nitrosative injury and antioxidant therapy in the management of diabetic neuropathy. J Investig Med 52 1 (2004) 33-44
56. Chander P.N., Gealekman O., Brodsky S.V., Elitok S., Tojo A., Crabtree M., et al. Nephropathy in Zucker diabetic fat rat is associated with oxidative and nitrosative stress: prevention by chronic therapy with a peroxynitrite scavenger ebselen. J Am Soc Nephrol 15 9 (2004) 2391-2403
57. Sugawara R., Hikichi T., Kitaya N., Mori F., Nagaoka T., Yoshida A., et al. Peroxynitrite decomposition catalyst, FP15, and poly(ADP-ribose) polymerase inhibitor, PJ34, inhibit leukocyte entrapment in the retinal microcirculation of diabetic rats. Curr Eye Res 29 1 (2004) 11-16
58. Nangle M.R., Cotter M.A., and Cameron N.E. Effects of the peroxynitrite decomposition catalyst, FeTMPyP, on function of corpus cavernosum from diabetic mice. Eur J Pharmacol 502 1-2 (2004) 143-148
59. Kiss L., and Szabo C. The pathogenesis of diabetic complications: the role of DNA injury and poly(ADP-ribose) polymerase activation in peroxynitrite-mediated cytotoxicity. Mem Inst Oswaldo Cruz 100 Suppl. 1 (2005) 29-37
60. Cohen R.A. Role of nitric oxide in diabetic complications. Am J Ther 12 6 (2005) 499-502
61. Obrosova I.G., Drel V.R., Pacher P., Ilnytska O., Wang Z.Q., Stevens M.J., et al. Oxidative-nitrosative stress and poly(ADP-ribose) polymerase (PARP) activation in experimental diabetic neuropathy: the relation is revisited. Diabetes 54 12 (2005) 3435-3441
62. Cai L. Suppression of nitrative damage by metallothionein in diabetic heart contributes to the prevention of cardiomyopathy. Free Radic Biol Med 41 6 (2006) 851-861
63. Drel V.R., Pacher P., Vareniuk I., Pavlov I., Ilnytska O., Lyzogubov V.V., et al. A peroxynitrite decomposition catalyst counteracts sensory neuropathy in streptozotocin-diabetic mice. Eur J Pharmacol 569 1-2 (2007) 48-58
64. Suarez-Pinzon W.L., Szabo C., and Rabinovitch A. Development of autoimmune diabetes in NOD mice is associated with the formation of peroxynitrite in pancreatic islet beta-cells. Diabetes 46 5 (1997) 907-911
65. Delaney C.A., Tyrberg B., Bouwens L., Vaghef H., Hellman B., and Eizirik D.L. Sensitivity of human pancreatic islets to peroxynitrite-induced cell dysfunction and death. FEBS Lett 394 3 (1996) 300-306
66. Suarez-Pinzon W.L., Mabley J.G., Strynadka K., Power R.F., Szabo C., and Rabinovitch A. An inhibitor of inducible nitric oxide synthase and scavenger of peroxynitrite prevents diabetes development in NOD mice. J Autoimmun 16 4 (2001) 449-455
67. Lakey J.R., Suarez-Pinzon W.L., Strynadka K., Korbutt G.S., Rajotte R.V., Mabley J.G., et al. Peroxynitrite is a mediator of cytokine-induced destruction of human pancreatic islet beta cells. Lab Invest 81 12 (2001) 1683-1692
68. Veluthakal R., Khan I., Tannous M., and Kowluru A. Functional inactivation by interleukin-1beta of glyceraldehyde-3-phosphate dehydrogenase in insulin-secreting cells. Apoptosis 7 3 (2002) 241-246
69. Mabley J.G., Southan G.J., Salzman A.L., and Szabo C. The combined inducible nitric oxide synthase inhibitor and free radical scavenger guanidinoethyldisulfide prevents multiple low-dose streptozotocin-induced diabetes in vivo and interleukin-1beta-induced suppression of islet insulin secretion in vitro. Pancreas 28 2 (2004) E39-E44
70. Mathews C.E., Suarez-Pinzon W.L., Baust J.J., Strynadka K., Leiter E.H., and Rabinovitch A. Mechanisms underlying resistance of pancreatic islets from ALR/Lt mice to cytokine-induced destruction. J Immunol 175 2 (2005) 1248-1256
71. Mihm M.J., Coyle C.M., Schanbacher B.L., Weinstein D.M., and Bauer J.A. Peroxynitrite induced nitration and inactivation of myofibrillar creatine kinase in experimental heart failure. Cardiovasc Res 49 4 (2001) 798-807
72. Ferdinandy P., Danial H., Ambrus I., Rothery R.A., and Schulz R. Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circ Res 87 3 (2000) 241-247
73. Ungvari Z., Gupte S.A., Recchia F.A., Batkai S., and Pacher P. Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol 3 3 (2005) 221-229
74. Zhang P., Xu X., Hu X., van Deel E.D., Zhu G., and Chen Y. Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure. Circ Res 100 7 (2007) 1089-1098
75. Pillai J.B., Isbatan A., Imai S., and Gupta M.P. Poly(ADP-ribose) polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by NAD+ depletion and reduced Sir2alpha deacetylase activity. J Biol Chem 280 52 (2005) 43121-43130
76. Priest D.G., Schmitz J.C., and Bunni M.A. Folate metabolites as modulators of antitumor drug activity. Adv Exp Med Biol 338 (1993) 693-698
77. Grogan L., Sotos G.A., and Allegra C.J. Leucovorin modulation of fluorouracil. Oncology (Williston Park) 7 8 (1993) 63-72
78. Cuzzocrea S., Mazzon E., Di P.R., Esposito E., Macarthur H., Matuschak G.M., et al. A role for nitric oxide-mediated peroxynitrite formation in a model of endotoxin-induced shock. J Pharmacol Exp Ther 319 1 (2006) 73-81
79. Szabo C., Salzman A.L., and Ischiropoulos H. Peroxynitrite-mediated oxidation of dihydrorhodamine 123 occurs in early stages of endotoxic and hemorrhagic shock and ischemia-reperfusion injury. FEBS Lett 372 2-3 (1995) 229-232
80. Szabo C. Potential role of the peroxynitrate-poly(ADP-ribose) synthetase pathway in a rat model of severe hemorrhagic shock. Shock 9 5 (1998) 341-344
81. Liaudet L., Soriano F.G., Szabo E., Virag L., Mabley J.G., Salzman A.L., et al. Protection against hemorrhagic shock in mice genetically deficient in poly(ADP-ribose)polymerase. Proc Natl Acad Sci USA 97 18 (2000) 10203-10208
82. Zhao K.S., Liu J., Yang G.Y., Jin C., Huang Q., and Huang X. Peroxynitrite leads to arteriolar smooth muscle cell membrane hyperpolarization and low vasoreactivity in severe shock. Clin Hemorheol Microcirc 23 2-4 (2000) 259-267
83. Potoka D.A., Nadler E.P., Upperman J.S., and Ford H.R. Role of nitric oxide and peroxynitrite in gut barrier failure. World J Surg 26 7 (2002) 806-811
84. Evgenov O.V., and Liaudet L. Role of nitrosative stress and activation of poly(ADP-ribose) polymerase-1 in cardiovascular failure associated with septic and hemorrhagic shock. Curr Vasc Pharmacol 3 3 (2005) 293-299
85. Virag L. Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies. Curr Vasc Pharmacol 3 3 (2005) 209-214
86. Woon E.C., and Threadgill M.D. Poly(ADP-ribose)polymerase inhibition - where now?. Curr Med Chem 12 20 (2005) 2373-2392
87. Oakley G.P.J., Adams M.J., and Dickinson C.M. More folic acid for everyone, now. J Nutr 126 3 (1996) 751S-755S
88. Lederle FA. Oral cobalamin for pernicious anemia. Medicine's best kept secret? JAMA 1991;265(1):94-5.
89. Oster K.A. A cardiologist considers psoriasis. Cutis 20 1 (1977) 39-40 45
90. Sirsjo A., Karlsson M., Gidlof A., Rollman O., and Torma H. Increased expression of inducible nitric oxide synthase in psoriatic skin and cytokine-stimulated cultured keratinocytes. Br J Dermatol 134 4 (1996) 643-648
91. Bruch-Gerharz D., Fehsel K., Suschek C., Michel G., Ruzicka T., and Kolb-Bachofen V. A proinflammatory activity of interleukin 8 in human skin: expression of the inducible nitric oxide synthase in psoriatic lesions and cultured keratinocytes. J Exp Med 184 5 (1996) 2007-2012
92. Lowes M.A., Chamian F., Abello M.V., Fuentes-Duculan J., Lin S.L., Nussbaum R., et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA 102 52 (2005) 19057-19062
93. Squadrito G.L., Cueto R., Splenser A.E., Valavanidis A., Zhang H., Uppu R.M., et al. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys 376 2 (2000) 333-337
94. Spitsin S., Hooper D.C., Leist T., Streletz L.J., Mikheeva T., and Koprowskil H. Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease. Mult Scler 7 5 (2001) 313-319
95. Scott G.S., Spitsin S.V., Kean R.B., Mikheeva T., Koprowski H., and Hooper D.C. Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc Natl Acad Sci U S A 99 25 (2002) 16303-16308
96. Mattle H.P., Lienert C., and Greeve I. Uric acid and multiple sclerosis. Ther Umsch 61 9 (2004) 553-555
97. Spitsin S., and Koprowski H. Role of uric acid in multiple sclerosis. Curr Top Microbiol Immunol 318 (2008) 325-342
98. Toncev G. Therapeutic value of serum uric acid levels increasing in the treatment of multiple sclerosis. Vojnosanit Pregl 63 10 (2006) 879-882
99. Wakai A., Winter D.C., Street J.T., O'Sullivan R.G., Wang J.H., and Redmond H.P. Inosine attenuates tourniquet-induced skeletal muscle reperfusion injury. J Surg Res 99 2 (2001) 311-315
100. Dowdall J.F., Winter D.C., and Bouchier-Hayes D.J. Inosine modulates gut barrier dysfunction and end organ damage in a model of ischemia-reperfusion injury. J Surg Res 108 1 (2002) 61-68
101. Shen H., Chen G.J., Harvey B.K., Bickford P.C., and Wang Y. Inosine reduces ischemic brain injury in rats. Stroke 36 3 (2005) 654-659
102. Hsiao G., Lin K.H., Chang Y., Chen T.L., Tzu N.H., Chou D.S., et al. Protective mechanisms of inosine in platelet activation and cerebral ischemic damage. Arterioscler Thromb Vasc Biol 25 9 (2005) 1998-2004
103. Szabo G., Stumpf N., Radovits T., Sonnenberg K., Gero D., Hagl S., et al. Effects of inosine on reperfusion injury after heart transplantation. Eur J Cardiothorac Surg 30 1 (2006) 96-102
104. Mabley J.G., Pacher P., Liaudet L., Soriano F.G., Hasko G., Marton A., et al. Inosine reduces inflammation and improves survival in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol 284 1 (2003) G138-G144
105. Hasko G., Kuhel D.G., Nemeth Z.H., Mabley J.G., Stachlewitz R.F., Virag L., et al. Inosine inhibits inflammatory cytokine production by a posttranscriptional mechanism and protects against endotoxin-induced shock. J Immunol 164 2 (2000) 1013-1019
106. Garcia S.F., Liaudet L., Marton A., Hasko G., Batista L.C., Deitch E.A., et al. Inosine improves gut permeability and vascular reactivity in endotoxic shock. Crit Care Med 29 4 (2001) 703-708
107. Liaudet L., Mabley J.G., Soriano F.G., Pacher P., Marton A., Hasko G., et al. Inosine reduces systemic inflammation and improves survival in septic shock induced by cecal ligation and puncture. Am J Respir Crit Care Med 164 7 (2001) 1213-1220
108. Darlington D.N., and Gann D.S. Inosine infusion prevents mortality in endotoxic shock. J Trauma 59 6 (2005) 1432-1435
109. Darlington D.N., and Gann D.S. Purine nucleosides stimulate Na/K ATPase, and prolong survival in hemorrhagic shock. J Trauma 58 5 (2005) 1055-1060
110. Yamagiwa T., Shimosegawa T., Satoh A., Kimura K., Sakai Y., and Masamune A. Inosine alleviates rat caerulein pancreatitis and pancreatitis-associated lung injury. J Gastroenterol 39 1 (2004) 41-49
111. Takeyama Y. Effect of inosine on pancreatitis: a powerful tool?. J Gastroenterol 39 1 (2004) 94-95
112. Schneider L., Pietschmann M., Hartwig W., Marcos S.S., Hackert T., Gebhard M.M., et al. Inosine reduces microcirculatory disturbance and inflammatory organ damage in experimental acute pancreatitis in rats. Am J Surg 191 4 (2006) 510-514
113. Mabley J.G., Rabinovitch A., Suarez-Pinzon W., Hasko G., Pacher P., Power R., et al. Inosine protects against the development of diabetes in multiple-low-dose streptozotocin and nonobese diabetic mouse models of type 1 diabetes. Mol Med 9 3-4 (2003) 96-104
114. Schneider S., and Klein H.H. Inosine improves islet xenograft survival in immunocompetent diabetic mice. Eur J Med Res 10 7 (2005) 283-286
115. Virag L., and Szabo C. Purines inhibit poly(ADP-ribose) polymerase activation and modulate oxidant-induced cell death. FASEB J 15 1 (2001) 99-107
116. Gomez G., and Sitkovsky M.V. Differential requirement for A2a and A3 adenosine receptors for the protective effect of inosine in vivo. Blood 102 13 (2003) 4472-4478
117. Annanmaki T., Muuronen A., and Murros K. Low plasma uric acid level in Parkinson's disease. Mov Disord 22 8 (2007) 1133-1137
118. Weisskopf M.G., O'Reilly E., Chen H., Schwarzschild M.A., and Ascherio A. Plasma urate and risk of Parkinson's disease. Am J Epidemiol 166 5 (2007) 561-567
119. de Lau L.M., Koudstaal P.J., Hofman A., and Breteler M.M. Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 58 5 (2005) 797-800
120. Davis J.W., Grandinetti A., Waslien C.I., Ross G.W., White L.R., and Morens D.M. Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease. Am J Epidemiol 144 5 (1996) 480-484
121. Anderson R.F., and Harris T.A. Dopamine and uric acid act as antioxidants in the repair of DNA radicals: implications in Parkinson's disease. Free Radic Res 37 10 (2003) 1131-1136
122. Church W.H., and Ward V.L. Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation. Brain Res Bull 33 4 (1994) 419-425
123. Kim T.S., Pae C.U., Yoon S.J., Jang W.Y., Lee N.J., Kim J.J., et al. Decreased plasma antioxidants in patients with Alzheimer's disease. Int J Geriatr Psychiatry 21 4 (2006) 344-348
124. Pulido R., Jimenez-Escrig A., Orensanz L., Saura-Calixto F., and Jimenez-Escrig A. Study of plasma antioxidant status in Alzheimer's disease. Eur J Neurol 12 7 (2005) 531-535
125. Luchsinger J.A., and Mayeux R. Cardiovascular risk factors and Alzheimer's disease. Curr Atheroscler Rep 6 4 (2004) 261-266
126. Craft S. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res 4 2 (2007) 147-152
127. Guo Z., Fratiglioni L., Zhu L., Fastbom J., Winblad B., and Viitanen M. Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use. Arch Neurol 56 8 (1999) 991-996
128. Khachaturian A.S., Zandi P.P., Lyketsos C.G., Hayden K.M., Skoog I., Norton M.C., et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol 63 5 (2006 May) 686-692
129. Reyes A.J. Potassium-retaining diuretics and incident Alzheimer disease. Arch Neurol 63 10 (2006) 1507
130. Reyes A.J. Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther 17 5-6 (2003) 397-414
131. Mielke M.M., Zandi P.P., Blennow K., Gustafson D., Sjogren M., Rosengren L., et al. Low serum potassium in mid life associated with decreased cerebrospinal fluid Abeta42 in late life. Alzheimer Dis Assoc Disord 20 1 (2006) 30-36
132. Rinaldi P., Polidori M.C., Metastasio A., Mariani E., Mattioli P., Cherubini A., et al. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging 24 7 (2003) 915-919
133. Tohgi H., Abe T., Takahashi S., and Kikuchi T. The urate and xanthine concentrations in the cerebrospinal fluid in patients with vascular dementia of the Binswanger type, Alzheimer type dementia, and Parkinson's disease. J Neural Transm Park Dis Dement Sect 6 2 (1993) 119-126
134. Degrell I., and Niklasson F. Purine metabolites in the CSF in presenile and senile dementia of Alzheimer type, and in multi infarct dementia. Arch Gerontol Geriatr 7 2 (1988) 173-178
135. Mander P., and Brown G.C. Activation of microglial NADPH oxidase is synergistic with glial iNOS expression in inducing neuronal death: a dual-key mechanism of inflammatory neurodegeneration. J Neuroinflammation 2 (2005) 20
136. Waugh WH. Inhibition of iron-catalyzed oxidations by attainable uric acid and ascorbic acid levels: therapeutic implications for Alzheimer's disease and late cognitive impairment. Gerontology 2008.
137. Garrel D.R., Verdy M., PetitClerc C., Martin C., Brule D., and Hamet P. Milk- and soy-protein ingestion: acute effect on serum uric acid concentration. Am J Clin Nutr 53 3 (1991) 665-669
138. Choi H.K., Liu S., and Curhan G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 52 1 (2005) 283-289
139. Choi H.K., Atkinson K., Karlson E.W., Willett W., and Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 350 11 (2004) 1093-1103
140. Chen H., Zhang S.M., Hernan M.A., Willett W.C., and Ascherio A. Diet and Parkinson's disease: a potential role of dairy products in men. Ann Neurol 52 6 (2002) 793-801
141. Chen H., O'Reilly E., McCullough M.L., Rodriguez C., Schwarzschild M.A., Calle E.E., et al. Consumption of dairy products and risk of Parkinson's disease. Am J Epidemiol 165 9 (2007) 998-1006
142. Park M., Ross G.W., Petrovitch H., White L.R., Masaki K.H., Nelson J.S., et al. Consumption of milk and calcium in midlife and the future risk of Parkinson disease. Neurology 64 6 (2005) 1047-1051
143. Becker B.F., Kastenbauer S., Kodel U., Kiesl D., and Pfister H.W. Urate oxidation in CSF and blood of patients with inflammatory disorders of the nervous system. Nucleosides Nucleotides Nucleic Acids 23 8-9 (2004) 1201-1204
144. Bakhiya A., Bahn A., Burckhardt G., and Wolff N. Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux. Cell Physiol Biochem 13 5 (2003) 249-256
145. Westholm D.E., Rumbley J.N., Salo D.R., Rich T.P., and Anderson G.W. Organic anion-transporting polypeptides at the blood-brain and blood-cerebrospinal fluid barriers. Curr Top Dev Biol 80 (2008) 135-170
146. Lopez JM, Garcia PJ, Mateos AF, Ramos HT, Pascual CI, Ortiz VJ. Purine transport through the blood-brain barrier in hypoxanthine phosphoribosyltransferase deficiency. Med Clin (Barc) 1989;92(5):167-70.
147. Aliefendioglu D., Gursoy T., Hayran K.M., and Aslan A.T. Can cerebrospinal fluid uric acid levels differentiate intraventricular hemorrhage from traumatic tap?. Biol Neonate 90 4 (2006) 268-272
148. Gibbs J.E., Jayabalan P., and Thomas S.A. Mechanisms by which 2′, 3′-dideoxyinosine (ddI) crosses the guinea-pig CNS barriers; relevance to HIV therapy. J Neurochem 84 4 (2003) 725-734
149. Johnson M.D., and Anderson B.D. Localization of purine metabolizing enzymes in bovine brain microvessel endothelial cells: an enzymatic blood-brain barrier for dideoxynucleosides?. Pharm Res 13 12 (1996) 1881-1886
150. Betz A.L. Identification of hypoxanthine transport and xanthine oxidase activity in brain capillaries. J Neurochem 44 2 (1985) 574-579
151. Spector R. Hypoxanthine transport through the blood-brain barrier. Neurochem Res 12 9 (1987) 791-796
152. Redzic Z.B., Gasic J.M., Segal M.B., Markovic I.D., Isakovic A.J., Rakic M.L., et al. The kinetics of hypoxanthine transport across the perfused choroid plexus of the sheep. Brain Res 925 2 (2002) 169-175
153. Kastenbauer S., and Pfister H.W. Protection against meningitis-associated central nervous system complications by uric acid. Med Hypotheses 58 5 (2002 May) 431
154. Shekarriz B, Stoller ML. Uric acid nephrolithiasis: current concepts and controversies. J Urol 2002;168(4 Pt 1):1307-14.
155. Nishino T., Okamoto K., Kawaguchi Y., Hori H., Matsumura T., Eger B.T., et al. Mechanism of the conversion of xanthine dehydrogenase to xanthine oxidase: identification of the two cysteine disulfide bonds and crystal structure of a non-convertible rat liver xanthine dehydrogenase mutant. J Biol Chem 280 26 (2005) 24888-24894
156. Ellestad M.H. Xanthine oxidase inhibitors the unappreciated treatment for heart failure. Cardiovasc Hematol Disord Drug Targets 7 4 (2007) 291-294
157. Sautin Y.Y., Nakagawa T., Zharikov S., and Johnson R.J. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 293 2 (2007) C584-C596
158. Khosla U.M., Zharikov S., Finch J.L., Nakagawa T., Roncal C., Mu W., et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 67 5 (2005) 1739-1742
159. Nakagawa T., Hu H., Zharikov S., Tuttle K.R., Short R.A., Glushakova O., et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 290 3 (2006) F625-F631
160. Heinig M., and Johnson R.J. Role of uric acid in hypertension, renal disease, and metabolic syndrome. Cleve Clin J Med 73 12 (2006) 1059-1064
161. Strazzullo P., and Puig J.G. Uric acid and oxidative stress: relative impact on cardiovascular risk?. Nutr Metab Cardiovasc Dis 17 6 (2007) 409-414
162. Baker J.F., Krishnan E., Chen L., and Schumacher H.R. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us?. Am J Med 118 8 (2005) 816-826
163. Wannamethee S.G. Serum uric acid and risk of coronary heart disease. Curr Pharm Des 11 32 (2005) 4125-4132
164. Schachter M. Uric acid and hypertension. Curr Pharm Des 11 32 (2005) 4139-4143
165. Feig DI, Mazzali M, Kang DH, Nakagawa T, Price K, Kannelis J, Johnson RJ. Serum uric acid: a risk factor and a target for treatment? J Am Soc Nephrol 2006;17(4 Suppl 2):S69-73.
166. Chien K.L., Chen M.F., Hsu H.C., Chang W.T., Su T.C., Lee Y.T., et al. Plasma uric acid and the risk of type 2 diabetes in a Chinese community. Clin Chem 54 2 (2008) 310-316
167. Dehghan A., van H.M., Sijbrands E.J., Hofman A., and Witteman J.C. High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care 31 2 (2008) 361-362
168. Puig J.G., and Martinez M.A. Hyperuricemia, gout and the metabolic syndrome. Curr Opin Rheumatol 20 2 (2008) 187-191
169. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114 12 (2004) 1752-1761
170. Kang D.H., Park S.K., Lee I.K., and Johnson R.J. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 16 12 (2005) 3553-3562
171. Muscelli E., Natali A., Bianchi S., Bigazzi R., Galvan A.Q., Sironi A.M., et al. Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens 9 8 (1996) 746-752
172. Reaven G.M. The kidney: an unwilling accomplice in syndrome X. Am J Kidney Dis 30 6 (1997) 928-931
173. Scott G.S., and Hooper D.C. The role of uric acid in protection against peroxynitrite-mediated pathology. Med Hypotheses 56 1 (2001) 95-100
174. George J., Carr E., Davies J., Belch J.J., and Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 114 23 (2006) 2508-2516
175. Waring W.S., McKnight J.A., Webb D.J., and Maxwell S.R. Lowering serum urate does not improve endothelial function in patients with type 2 diabetes. Diabetologia 50 12 (2007) 2572-2579
176. Waring W.S., Adwani S.H., Breukels O., Webb D.J., and Maxwell S.R. Hyperuricaemia does not impair cardiovascular function in healthy adults. Heart 90 2 (2004) 155-159
177. Waring W.S., McKnight J.A., Webb D.J., and Maxwell S.R. Uric acid restores endothelial function in patients with type 1 diabetes and regular smokers. Diabetes 55 11 (2006) 3127-3132
178. Frank D.A. Nucleic Acid Therapy in Aging and Degenerative Disease (1968), Psychological Library, New York
179. Christen S., Woodall A.A., Shigenaga M.K., Southwell-Keely P.T., Duncan M.W., and Ames B.N. Gamma-tocopherol traps mutagenic electrophiles such as NO(X) and complements alpha-tocopherol: physiological implications. Proc Natl Acad Sci USA 94 7 (1997) 3217-3222
180. Christen S., Jiang Q., Shigenaga M.K., and Ames B.N. Analysis of plasma tocopherols alpha, gamma, and 5-nitro-gamma in rats with inflammation by HPLC coulometric detection. J Lipid Res 43 11 (2002) 1978-1985
181. Scheidegger R., Pande A.K., Bounds P.L., and Koppenol W.H. The reaction of peroxynitrite with zeaxanthin. Nitric Oxide 2 1 (1998) 8-16
182. Hiramoto K., Tomiyama S., and Kikugawa K. Effective inhibition by beta-carotene of cellular DNA breaking induced by peroxynitrous acid. Free Radic Res 30 1 (1999) 21-27
183. Panasenko O.M., Sharov V.S., Briviba K., and Sies H. Interaction of peroxynitrite with carotenoids in human low density lipoproteins. Arch Biochem Biophys 373 1 (2000) 302-305
184. Muzandu K., Ishizuka M., Sakamoto K.Q., Shaban Z., El B.K., Kazusaka A., et al. Effect of lycopene and beta-carotene on peroxynitrite-mediated cellular modifications. Toxicol Appl Pharmacol 215 3 (2006) 330-340
185. Santocono M., Zurria M., Berrettini M., Fedeli D., and Falcioni G. Lutein, zeaxanthin and astaxanthin protect against DNA damage in SK-N-SH human neuroblastoma cells induced by reactive nitrogen species. J Photochem Photobiol B 88 1 (2007) 1-10
186. McCarty MF. Scavenging of peroxynitrite-derived radicals by flavonoids may support endothelial NO synthase activity, contributing to the vascular protection associated with high fruit and vegetable intakes. Med Hypotheses, in press.
187. Lanone S., Bloc S., Foresti R., Almolki A., Taille C., Callebert J., et al. Bilirubin decreases nos2 expression via inhibition of NAD(P)H oxidase: implications for protection against endotoxic shock in rats. FASEB J 19 13 (2005) 1890-1892
188. Matsumoto H., Ishikawa K., Itabe H., and Maruyama Y. Carbon monoxide and bilirubin from heme oxygenase-1 suppresses reactive oxygen species generation and plasminogen activator inhibitor-1 induction. Mol Cell Biochem 291 1-2 (2006) 21-28
189. Jiang F., Roberts S.J., Datla S., and Dusting G.J. NO modulates NADPH oxidase function via heme oxygenase-1 in human endothelial cells. Hypertension 48 5 (2006) 950-957
190. McCarty M.F. Iatrogenic Gilbert sydrome - a strategy for reducing vascular and cancer risk by increasing plasma unconjugated bilirubin. Med Hypotheses 69 5 (2007) 974-994
191. McCarty M.F. Clinical potential of spirulina as a source of phycocyanobilin. J Med Food 10 4 (2007) 566-570
192. Adams J.S., Ren S.Y., Arbelle J.E., Shany S., and Gacad M.A. Coordinate regulation of nitric oxide and 1, 25-dihydroxyvitamin D production in the avian myelomonocytic cell line HD-11. Endocrinology 136 5 (1995 May) 2262-2269
193. Overbergh L., Decallonne B., Valckx D., Verstuyf A., Depovere J., Laureys J., et al. Identification and immune regulation of 25-hydroxyvitamin D-1-alpha-hydroxylase in murine macrophages. Clin Exp Immunol 120 1 (2000) 139-146
194. Fritsche J., Mondal K., Ehrnsperger A., Andreesen R., and Kreutz M. Regulation of 25-hydroxyvitamin D3-1 alpha-hydroxylase and production of 1 alpha, 25-dihydroxyvitamin D3 by human dendritic cells. Blood 102 9 (2003) 3314-3316
195. Stoffels K., Overbergh L., Giulietti A., Verlinden L., Bouillon R., and Mathieu C. Immune regulation of 25-hydroxyvitamin-D3-1alpha-hydroxylase in human monocytes. J Bone Miner Res 21 1 (2006) 37-47
196. Liu P.T., Stenger S., Li H., Wenzel L., Tan B.H., Krutzik S.R., et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311 5768 (2006) 1770-1773
197. Overbergh L., Stoffels K., Waer M., Verstuyf A., Bouillon R., and Mathieu C. Immune regulation of 25-hydroxyvitamin D-1alpha-hydroxylase in human monocytic THP1 cells: mechanisms of interferon-gamma-mediated induction. J Clin Endocrinol Metab 91 9 (2006) 3566-3574
198. Garcion E., Nataf S., Berod A., Darcy F., and Brachet P. 1, 25-Dihydroxyvitamin D3 inhibits the expression of inducible nitric oxide synthase in rat central nervous system during experimental allergic encephalomyelitis. Brain Res Mol Brain Res 45 2 (1997) 255-267
199. Garcion E., Sindji L., Montero-Menei C., Andre C., Brachet P., and Darcy F. Expression of inducible nitric oxide synthase during rat brain inflammation: regulation by 1, 25-dihydroxyvitamin D3. Glia 22 3 (1998) 282-294
200. Chang JM, Kuo MC, Kuo HT, Hwang SJ, Tsai JC, Chen HC, Lai YH. 1-alpha,25-Dihydroxyvitamin D3 regulates inducible nitric oxide synthase messenger RNA expression and nitric oxide release in macrophage-like RAW 264.7 cells. J Lab Clin Med 2004;143(1):14-22.
201. Pedersen L.B., Nashold F.E., Spach K.M., and Hayes C.E. 1, 25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by inhibiting chemokine synthesis and monocyte trafficking. J Neurosci Res 85 11 (2007) 2480-2490
202. Quinn M.R., Liu Y., Barua M., and Serban V. Taurine chloramine inhibits production of inflammatory mediators and iNOS gene expression in alveolar macrophages; a tale of two pathways: part II, IFN-gamma signaling through JAK/Stat. Adv Exp Med Biol 526 (2003) 349-356
203. Quinn M.R., Barua M., Liu Y., and Serban V. Taurine chloramine inhibits production of inflammatory mediators and iNOS gene expression in alveolar macrophages; a tale of two pathways: part I, NF-kappaB signaling. Adv Exp Med Biol 526 (2003) 341-348
204. Kim JW, Kim C. Inhibition of LPS-induced NO production by taurine chloramine in macrophages is mediated though Ras-ERK-NF-kappaB. Biochem Pharmacol 2005;70(9):1352-60.
205. Gurujeyalakshmi G, Wang Y, Giri SN. Taurine and niacin block lung injury and fibrosis by down-regulating bleomycin-induced activation of transcription nuclear factor-kappaB in mice. J Pharmacol Exp Ther 2000;293(1):82-90.
206. Gurujeyalakshmi G, Wang Y, Giri SN. Suppression of bleomycin-induced nitric oxide production in mice by taurine and niacin. Nitric Oxide;4(4):399-411.
207. Liu HY, Chi FL, Gao WY. Taurine attenuates aminoglycoside ototoxicity by inhibiting inducible nitric oxide synthase expression in the cochlea. Neuroreport 2008;19(1):117-20.
208. Erdamar H, Turkozkan N, Balabanli B, Ozan G, Bircan FS. The relationship between taurine and 3-nitrotyrosine level of hepatocytes in experimental endotoxemia. Neurochem Res 2007;32(11):1965-68.
209. Szabo C, Ischiropoulos H, Radi R. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discov 2007;6(8):662-80.
210. Fink MP. Reactive oxygen species as mediators of organ dysfunction caused by sepsis, acute respiratory distress syndrome, or hemorrhagic shock: potential benefits of resuscitation with Ringer's ethyl pyruvate solution. Curr Opin Clin Nutr Metab Care 2002;5(2):167-74.
211. Reiter RJ, Tan DX, Cabrera J, D'Arpa D, Sainz RM, Mayo JC, Ramos S. The oxidant/antioxidant network: role of melatonin. Biol Signals Recept 1999;8(1-2):56-63.
212. Reiter RJ, Tan DX, Osuna C, Gitto E. Actions of melatonin in the reduction of oxidative stress. A review. J Biomed Sci 2000;7(6):444-58.
213. Khan SG, Katiyar SK, Agarwal R, Mukhtar H. Enhancement of antioxidant and phase II enzymes by oral feeding of green tea polyphenols in drinking water to SKH-1 hairless mice: possible role in cancer chemoprevention. Cancer Res 1992;52(14):4050-52.
214. Frei B, Higdon JV. Antioxidant activity of tea polyphenols in vivo: evidence from animal studies. J Nutr 2003;133(10):3275S-84S.
215. Chen C, Pung D, Leong V, Hebbar V, Shen G, Nair S, Li W, Kong AN. Induction of detoxifying enzymes by garlic organosulfur compounds through transcription factor Nrf2: effect of chemical structure and stress signals. Free Radic Biol Med 2004;37(10):1578-90.
216. Tsai CW, Yang JJ, Chen HW, Sheen LY, Lii CK. Garlic organosulfur compounds upregulate the expression of the pi class of glutathione S-transferase in rat primary hepatocytes. J Nutr 2005;135(11):2560-5.
217. Herman-Antosiewicz A, Powolny AA, Singh SV. Molecular targets of cancer chemoprevention by garlic-derived organosulfides. Acta Pharmacol Sin 2007;28(9):1355-64.
218. Fahey JW, Zhang Y, Talalay P. Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc Natl Acad Sci USA 1997;94(19):10367-72.
219. Shapiro T.A., Fahey J.W., nkova-Kostova A.T., Holtzclaw W.D., Stephenson K.K., Wade K.L., et al. Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: a clinical phase I study. Nutr Cancer 55 1 (2006) 53-62
220. nkova-Kostova AT, Fahey JW, Wade KL, Jenkins SN, Shapiro TA, Fuchs EJ, Kerns ML, Talalay P. Induction of the phase 2 response in mouse and human skin by sulforaphane-containing broccoli sprout extracts. Cancer Epidemiol Biomarkers Prev 2007;16(4):847-51.
221. Yoon H.Y., Kang N.I., Lee H.K., Jang K.Y., Park J.W., and Park B.H. Sulforaphane protects kidneys against ischemia-reperfusion injury through induction of the Nrf2-dependent phase 2 enzyme. Biochem Pharmacol 75 11 (2008) 2214-2223
222. Flier J, Van Muiswinkel FL, Jongenelen CA, Drukarch B. The neuroprotective antioxidant alpha-lipoic acid induces detoxication enzymes in cultured astroglial cells. Free Radic Res 2002;36(6):695-9.
223. Cao Z, Tsang M, Zhao H, Li Y. Induction of endogenous antioxidants and phase 2 enzymes by alpha-lipoic acid in rat cardiac H9C2 cells: protection against oxidative injury. Biochem Biophys Res Commun 2003;310(3):979-85.
224. Jia Z., Hallur S., Zhu H., Li Y., and Misra H.P. Potent upregulation of glutathione and NAD(P)H:quinone oxidoreductase 1 by alpha-lipoic acid in human neuroblastoma SH-SY5Y cells: protection against neurotoxicant-elicited cytotoxicity. Neurochem Res 33 5 (2008) 790-800
225. Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M, Maus J, Samigullin R. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006;29(11):2365-70.
226. Ruessmann HJ. Switching from pathogenetic treatment with alpha-lipoic acid to gabapentin and other analgesics in painful diabetic neuropathy: a real-world study in outpatients. J Diabetes Compl 2008;226.
227. Vincent HK, Bourguignon CM, Vincent KR, Taylor AG. Effects of alpha-lipoic acid supplementation in peripheral arterial disease: a pilot study. J Altern Complement Med 2007;13(5):577-84.
228. Hager K, Kenklies M, McAfoose J, Engel J, Munch G. Alpha-lipoic acid as a new treatment option for Alzheimer's disease - a 48 months follow-up analysis. J Neural Transm Suppl 2007;(72):189-93.
229. Magis D, Ambrosini A, Sandor P, Jacquy J, Laloux P, Schoenen J. A randomized double-blind placebo-controlled trial of thioctic acid in migraine prophylaxis. Headache 2007;47(1):52-7.
230. Talalay P, Fahey JW, Holtzclaw WD, Prestera T, Zhang Y. Chemoprotection against cancer by phase 2 enzyme induction. Toxicol Lett 1995;82-83:173-9.
231. Wu L, Noyan Ashraf MH, Facci M, Wang R, Paterson PG, Ferrie A, Juurlink BH. Dietary approach to attenuate oxidative stress, hypertension, and inflammation in the cardiovascular system. Proc Natl Acad Sci USA 2004;101(18):7094-99.
232. Priyadarshi S., Valentine B., Han C., Fedorova O.V., Bagrov A.Y., Liu J., et al. Effect of green tea extract on cardiac hypertrophy following 5/6 nephrectomy in the rat. Kidney Int 63 5 (2003 May) 1785-1790
233. Negishi H, Xu JW, Ikeda K, Njelekela M, Nara Y, Yamori Y. Black and green tea polyphenols attenuate blood pressure increases in stroke-prone spontaneously hypertensive rats. J Nutr 2004;134(1):38-42.
234. Potenza M.A., Marasciulo F.L., Tarquinio M., Tiravanti E., Colantuono G., Federici A., et al. EGCG, a green tea polyphenol, improves endothelial function and insulin sensitivity, reduces blood pressure, and protects against myocardial I/R injury in SHR. Am J Physiol Endocrinol Metab 292 5 (2007) E1378-E1387
235. Ikeda M, Suzuki C, Umegaki K, Saito K, Tabuchi M, Tomita T. Preventive effects of green tea catechins on spontaneous stroke in rats. Med Sci Monit 2007;13(2):BR40-45.
236. Hao J, Kim CH, Ha TS, Ahn HY. Epigallocatechin-3 gallate prevents cardiac hypertrophy induced by pressure overload in rats. J Vet Sci 2007;8(2):121-9.
237. Basu A, Lucas EA. Mechanisms and effects of green tea on cardiovascular health. Nutr Rev 2007;65(8 Pt 1):361-75.
238. Miura Y, Chiba T, Tomita I, Koizumi H, Miura S, Umegaki K, Hara Y, Ikeda M, Tomita T. Tea catechins prevent the development of atherosclerosis in apoprotein E-deficient mice. J Nutr 2001;131(1):27-32.
239. Yamabe N, Yokozawa T, Oya T, Kim M. Therapeutic potential of (-)-epigallocatechin 3-O-gallate on renal damage in diabetic nephropathy model rats. J Pharmacol Exp Ther 2006;319(1):228-36.
240. Mandel S, Youdim MB. Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases. Free Radic Biol Med 2004;37(3):304-17.
241. Weinreb O, Mandel S, Amit T, Youdim MB. Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. J Nutr Biochem 2004;15(9):506-16.
242. Bastianetto S, Yao ZX, Papadopoulos V, Quirion R. Neuroprotective effects of green and black teas and their catechin gallate esters against beta-amyloid-induced toxicity. Eur J Neurosci 2006;23(1):55-64.
243. Sutherland B.A., Rahman R.M., and Appleton I. Mechanisms of action of green tea catechins, with a focus on ischemia-induced neurodegeneration. J Nutr Biochem 17 5 (2006) 291-306
244. Borek C. Garlic reduces dementia and heart-disease risk. J Nutr 2006;136(3 Suppl):810S-2S.
245. Efendy JL, Simmons DL, Campbell GR, Campbell JH. The effect of the aged garlic extract, 'Kyolic', on the development of experimental atherosclerosis. Atherosclerosis 1997;132(1):37-42.
246. Campbell JH, Efendy JL, Smith NJ, Campbell GR. Molecular basis by which garlic suppresses atherosclerosis. J Nutr 2001 ;131(3s):1006S-9S.
247. Williams MJ, Sutherland WH, McCormick MP, Yeoman DJ, de Jong SA. Aged garlic extract improves endothelial function in men with coronary artery disease. Phytother Res 2005;19(4):314-9.
248. Borek C. Antioxidant health effects of aged garlic extract. J Nutr 2001;131(3s):1010S-5S.
249. Wollin SD, Jones PJ. Alpha-lipoic acid and cardiovascular disease. J Nutr 2003;133(11):3327-30.
250. Kowluru RA, Odenbach S. Effect of long-term administration of alpha-lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats. Diabetes 2004;53(12):3233-8.
251. Kamenova P. Improvement of insulin sensitivity in patients with type 2 diabetes mellitus after oral administration of alpha-lipoic acid. Hormones (Athens) 2006;5(4):251-8.
252. Tardif JC, Rheaume E. Lipoic acid supplementation and endothelial function. Br J Pharmacol 2008;153(8):1587-8.
253. Foster TS. Efficacy and safety of alpha-lipoic acid supplementation in the treatment of symptomatic diabetic neuropathy. Diabetes Educ 2007;33(1):111-7.
254. Packer L., Tritschler H.J., and Wessel K. Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med 22 1-2 (1997) 359-378
255. Holmquist L, Stuchbury G, Berbaum K, Muscat S, Young S, Hager K, Engel J, Munch G. Lipoic acid as a novel treatment for Alzheimer's disease and related dementias. Pharmacol Ther 2007;113(1):154-64.
256. Grossman E, Laudon M, Yalcin R, Zengil H, Peleg E, Sharabi Y, Kamari Y, Shen-Orr Z, Zisapel N. Melatonin reduces night blood pressure in patients with nocturnal hypertension. Am J Med 2006;119(10):898-902.
257. Simko F, Paulis L. Melatonin as a potential antihypertensive treatment. J Pineal Res 2007;42(4):319-22.
258. Tengattini S, Reiter RJ, Tan DX, Terron MP, Rodella LF, Rezzani R. Cardiovascular diseases: protective effects of melatonin. J Pineal Res 2008;44(1):16-25.
259. Ha H, Yu MR, Kim KH. Melatonin and taurine reduce early glomerulopathy in diabetic rats. Free Radic Biol Med 1999;26(7-8):944-50.
260. Paskaloglu K, Sener G, yangolu-Dulger G. Melatonin treatment protects against diabetes-induced functional and biochemical changes in rat aorta and corpus cavernosum. Eur J Pharmacol 2004;499(3):345-4.
261. Kurcer Z, Parlakpinar H, Vardi N, Tasdemir S, Iraz M, Fadillioglu E, Baba F, Gul M. Protective effects of chronic melatonin treatment against renal ischemia/reperfusion injury in streptozotocin-induced diabetic rats. Exp Clin Endocrinol Diabetes 2007;115(6):365-71.
262. Gumustekin M, Tekmen I, Guneli E, Tugyan K, Topcu A, Ergonen AT, Ozdemir MH, Uysal N, Bediz CS. Short-term melatonin treatment improved diabetic nephropathy but did not affect hemorheological changes in diabetic rats. Pharmazie 2007;62(9):693-8.
263. Gupta YK, Gupta M, Kohli K. Neuroprotective role of melatonin in oxidative stress vulnerable brain. Ind J Physiol Pharmacol 2003;47(4):373-86.
264. Srinivasan V., Pandi-Perumal S.R., Maestroni G.J., Esquifino A.I., Hardeland R., and Cardinali D.P. Role of melatonin in neurodegenerative diseases. Neurotox Res 7 4 (2005) 293-318
265. Mayo JC, Sainz RM, Tan DX, Antolin I, Rodriguez C, Reiter RJ. Melatonin and Parkinson's disease. Endocrine 2005;27(2):169-78.
266. Wang JZ, Wang ZF. Role of melatonin in Alzheimer-like neurodegeneration. Acta Pharmacol Sin 2006;27(1):41-9.
267. Srinivasan V., Pandi-Perumal S.R., Cardinali D.P., Poeggeler B., and Hardeland R. Melatonin in Alzheimer's disease and other neurodegenerative disorders. Behav Brain Funct 2 (2006) 15
268. Xue M., Qian Q., Antonysunil A., Rabbani N., Babaei-Jadidi R., and Thornalley P.J. Activation of NF-E2-related factor-2 reverses biochemical dysfunction of endothelial cells induced by hyperglycemia linked to vascular disease. Diabetes 57 10 (2008) 2809-2817